Glucagon‐like peptide‐1 (GLP‐1) plays a major role in appetite and glucose homeostasis and recently the USFDA approved GLP‐1 agonists for the treatment of obesity and type 2 diabetes. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.